KHRNF (Khiron Life Sciences) Book Value per Share: $0.09 (As of Sep. 2022)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Khiron Life Sciences Book Value per Share?

Khiron Life Sciences KHRNF -90.00% Book Value per Share is $0.09 as of Sep. 2022.

Khiron Life Sciences's book value per share for the quarter that ended in Sep. 2022 was $0.09.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the book value growth rate using book value per share data.

Khiron Life Sciences's current price is $1.0E-5. Its book value per share for the quarter that ended in Sep. 2022 was $0.09. Hence, today's PB Ratio of Khiron Life Sciences is 0.00.


Khiron Life Sciences  (OTCPK:KHRNF) Book Value per Share Explanation

Usually a company's book value and Tangible Book per Share may not reflect its true value. The assets may be carried on the balance sheets at the original cost minus depreciation. This may underestimate the true economic values of the assets. It also may over-estimate their true economic value because the assets can become obsolete.

For financial companies such as banks and insurance companies, their assets may be reported in current market value of the assets owned. Book values of financial companies are more accurate indicator of the economic value of the company.


Khiron Life Sciences Book Value per Share Related Terms


Khiron Life Sciences Book Value per Share Historical Data

* Premium members only.

The historical data trend for Khiron Life Sciences's Book Value per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Khiron Life Sciences Book Value per Share Chart

Khiron Life Sciences Annual Data
Trend May12 May13 May14 May15 May16 May17 Dec18 Dec19 Dec20 Dec21
Book Value per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.42 0.25 0.46 0.33 0.15

Khiron Life Sciences Quarterly Data
Nov17 Feb18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22
Book Value per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.24 0.15 0.13 0.11 0.09

KHRNF vs ZTS, CTLT, VTRS: Book Value per Share Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Khiron Life Sciences's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Khiron Life Sciences PB Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Khiron Life Sciences's PB Ratio distribution charts can be found below:

* The bar in red indicates where Khiron Life Sciences's PB Ratio falls into.



Khiron Life Sciences Book Value per Share Calculation

Khiron Life Sciences's Book Value Per Share for the fiscal year that ended in Dec. 2021 is calculated as:

Book Value Per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(26.04-0.00)/179.26
=0.15

Khiron Life Sciences's Book Value Per Share for the quarter that ended in Sep. 2022 is calculated as:

Book Value Per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(20.32-0.00)/217.14
=0.09

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Theoretically it is what the shareholders will receive if the company is liquidated. Total Stockholders Equity is a balance sheet item and equal to Total Assets less Total Liabilities of the company.

Book value may include intangible items which may come from the company's past acquisitions. Book value less intangibles is called Tangible Book.

Frequently Asked Questions Learn more about Book Value per Share →
What does a Book Value per Share of $0.09 mean?
Khiron Life Sciences (KHRNF) has a Book Value per Share of $0.09 as of Sep. 2022. Book value per share gives the per-share value of a company's stockholder equity. View historical data on Khiron Life Sciences and its competitors.
Is Khiron Life Sciences' Book Value per Share too high?
Khiron Life Sciences' current Book Value per Share is $0.09.
How does Khiron Life Sciences' Book Value per Share compare to ZTS and CTLT?
Khiron Life Sciences' Book Value per Share of $0.09 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Book Value per Share for a Drug Manufacturers company?
A good Book Value per Share depends on the Drug Manufacturers industry context. However, Book Value per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Book Value per Share mean?
A high Book Value per Share can signal that a stock is expensive relative to its fundamentals. Book value per share gives the per-share value of a company's stockholder equity. View historical data on Khiron Life Sciences and its competitors. Khiron Life Sciences's current Book Value per Share is $0.09. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Khiron Life Sciences stock overvalued right now?
Khiron Life Sciences (KHRNF) has a current Book Value per Share of $0.09. The current Book Value per Share is $0.09. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Book Value per Share calculated?
Book Value per Share is calculated from a company's financial statements. For Khiron Life Sciences (KHRNF), the current Book Value per Share is $0.09 as of Sep. 2022. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Khiron Life Sciences Business Description

Address 2300 - 500 Burrard Street, Vancouver, BC, CAN, V6C 2B5
Khiron Life Sciences Corp is a vertically integrated medical company with core operations in Latin America and Europe, The company's platform leverages medical health clinics and proprietary telemedicine platforms, Khiron combines a patient-oriented approach, physician education programs, scientific, product innovation, and cannabis operations expertise to drive prescriptions and brand loyalty with patients worldwide. The company has a presence in Mexico, Peru, Germany, the United Kingdom, and Brazil.